Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

The analyst highlights that Lilly’s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...

Eli Lilly (NYSE:LLY) experienced a 2% decline last week, a movement that contrasts with a broader market drop of 3%. The ...

Zoom out: The positive results sent Lilly's stock soaring 16% Thursday to $852. Bank of America's Anderson projected 2030 ...

Eli Lilly (LLY) is up 14.1%, or $103.95 to $838.85.Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart ...

Shares of Eli Lilly (LLY) jumped on Thursday morning after the company announced topline Phase 3 results from ACHIEVE-1, evaluating the safety ...

If approved, the pill is expected to be far easier to administer than current injectables — and far easier to manufacture.

Eli Lilly shares are now positive for the year, up 10% since the start of January.

One man’s trash may be another man’s treasure, but dumpster diving when investing carries risks. You have to wade through a ...

(Reuters) -Eli Lilly said on Thursday its experimental pill, orforglipron, led to a weight loss of nearly 8% at the highest ...